尊龙凯时 - 人生就是搏!

Multiple myeloma and non-Hodgkin's lymphoma (NHL)
Single Agent/Combination Therapy

Phase I

Advanced breast cancer
Combination Therapy (dalpiciclib)

Phase I

Prevention of bone-related events in solid tumor with bone metastases and multiple myeloma
Single Agent

Phase I

Bladder caner
Single Agent

Phase I

Metastatic castration-resistant prostate cancer
Single Agent

Phase II

Recurrent ovarian cancer
Combination Therapy (bevacizumab)

Phase II

Advanced prostate cancer
Combination Therapy

Phase II

Advanced solid tumors
Single Agent

Phase I

HER2-expressing or -mutated advanced solid tumors
Combination Therapy

Phase II

HER2-expressing or -mutated solid tumors
Single Agent

Phase I

Non-muscle invasive bladder cancer
Combination Therapy (BCG bladder perfusion)

Phase II

B-cell non-Hodgkin lymphoma
Combination Therapy

Phase II

B-cell non-Hodgkin lymphoma
Single Agent

Phase I
US

B-cell lymphoma
Single Agent

Phase I

EGFR-mutated advanced or metastatic non-small cell lung cancer that has failed EGFR TK therapy
Single Agent

Phase III

Advanced solid tumors
Combination Therapy

Phase II

Advanced or metastatic solid tumors
Single Agent

Phase I

Advanced solid tumors
Single Agent

Phase I
Japan and Korea

Platinum-sensitive recurrent epithelial ovarian cancer
Single Agent or Combination Therapy with carboplatin

Phase III

Platinum-resistant recurrent epithelial ovarian cancer
Single Agent

Phase III

Advanced solid tumors
Single Agent

Phase II
US, Australia

Advanced solid tumors
Combination Therapy

Phase II

2nd-line CLDN18.2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma
Single Agent

Phase III

CLDN18.2-positive advanced solid tumors
Combination Therapy (adebrelimab)

Phase III

Advanced pancreatic cancer
Single Agent

Phase I

Advanced solid tumors
Single Agent

Phase I
US, Australia, China

2nd/3rd-line locally advanced or metastatic urothelial carcinoma
Single Agent

Phase III

Advanced solid tumors
Single Agent

Phase II
US

Advanced gynecologic malignancies
Single Agent

Phase II

Locally advanced or metastatic non-small cell lung cancer
Combination Therapy

Phase II

Advanced urothelial carcinoma
Combination Therapy (adebrelimab)

Phase II

Locally advanced or metastatic esophageal cancer
Combination Therapy (adebrelimab)

Phase II

Advanced solid tumors
Single Agent

Phase I

Relapsed and refractory peripheral T-cell lymphoma
Single Agent

NDA/BLA Filed

T-cell lymphoma
Combination Therapy

Phase II

Relapsed and refractory follicular lymphoma
Single Agent

Phase II

Refractory/relapsed T-cell lymphoma
Single Agent

Phase I

1st-line advanced or metastatic gastric cancer (GC) or gastroesophageal junction cancer
Combination Therapy (chemotherapy)

NDA/BLA Filed

Advanced solid tumors
Single Agent

Phase I
Australia

2nd-line and subsequent locally advanced or metastatic HER2-mutated adult non-small cell lung cancer
Single Agent

NDA/BLA Filed

HER2-positive metastatic breast cancer
Single Agent

Phase III

HER2-low recurrent/metastatic breast cancer
Single Agent

Phase III

Adjuvant therapy for HER2-positive breast cancer
Single Agent

Phase III

HER2-positive recurrent or metastatic breast cancer
Combination Therapy

Phase III

3rd-line HER2-positive advanced colorectal cancer
Single Agent

Phase III

1st-line treatment for HER2-mutated advanced or metastatic non-small cell lung cancer
Single Agent

Phase III

Advanced solid tumors with HER2 expression
Combination Therapy (fuzuloparib)

Phase II

HER2-low metastatic or unresectable breast cancer
Combination Therapy

Phase II

HER2-expressing gynecological malignancies
Single Agent

Phase II

HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma
Combination Therapy (adebrelimab+chemotherapy)

Phase II

1st-line HER2 mutated, amplified, or overexpressed advanced non-small cell lung cancer
Combination Therapy (pyrotinib/adebrelimab)

Phase II

Locally advanced unresectable or recurrent metastatic biliary tract cancer with HER2 expression/amplification
Single Agent

Phase II

Gastric cancer or adenocarcinoma of the gastroesophageal junction and colorectal cancer
Single Agent

Phase I

Advanced solid tumors
Single Agent

Phase I
US, Australia, Asia Pacific (including China)

Prevention of highly emetogenic chemotherapy-induced nausea and vomiting
Single Agent (FDC)

NDA/BLA Filed

Prevention of nausea and vomiting caused by antineoplastic drugs with moderate risk of vomiting
Single Agent (FDC)

Phase III

HER2-negative metastatic breast cancer adult patients with germline BRCA mutations
Combination Therapy (fuzuloparib)

Marketed

Advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma progressed or relapsed after at least 2Ls of systematic chemotherapy
Single Agent

Marketed

Advanced hepatocellular carcinoma failed or intolerable after at least first-line systemic therapy
Single Agent

Marketed

1st-line unresectable or metastatic hepatocellular carcinoma
Combination Therapy (camrelizumab)

Marketed

1st-line unresectable or metastatic hepatocellular carcinoma
Combination Therapy (camrelizumab)

NDA/BLA Filed
US, Europe, and Asia Pacific (including China)

Unresectable hepatocellular carcinoma
Combination Therapy (TACE+camrelizumab)

Phase III

Relapsed or metastatic advanced HER2-positive breast cancer patients without previous HER2 treatment
Combination Therapy (trastuzumab+docetaxel)

Marketed

Relapsed or metastatic HER2-positive breast cancer with previous trastuzumab treatment
Combination Therapy (capecitabine)

Marketed

Neoadjuvant treatment for early or locally advanced HER2-positive breast cancer
Combination Therapy (trastuzumab+docetaxel)

Marketed

Extended adjuvant therapy for HER2-positive breast cancer
Single Agent

Phase III

Advanced non-squamous non-small cell lung cancer with HER2 mutation
Single Agent

Phase III
US, Europe, and Asia Pacific (including China)

Relapsed and refractory classical Hodgkin lymphoma after at least two systematic therapies
Single Agent

Marketed

Advanced hepatocellular carcinoma after sorafenib and/or lenvatinib and/or oxaliplatin-containing chemotherapy treatments
Single Agent

Marketed

1st-line unresectable locally advanced or metastatic EGFR-mut negative ALK-negative NSCLC
Combination Therapy (pemetrexed+carboplatin)

Marketed

Locally advanced or metastatic esophageal adenocarcinoma progressed after or intolerable to 1st-line treatment
Single Agent

Marketed

Advanced nasopharyngeal carcinoma progressed after or intolerable to 2nd-line+ chemotherapy
Single Agent

Marketed

1st-line locally relapsed or metastatic nasopharyngeal carcinoma
Combination Therapy (cisplatin+gemcitabine)

Marketed

1st-line unresectable locally advanced/relapsed or metastatic esophageal squamous cell carcinoma
Combination Therapy (cisplatin+paclitaxel)

Marketed

1st-line locally advanced/metastatic squamous non-small cell lung cancer
Combination Therapy (carboplatin+paclitaxel)

Marketed

1st-line unresectable or metastatic hepatocellular carcinoma
Combination Therapy (apatinib)

Marketed

Recurrent metastatic cervical cancer
Combination Therapy (famitinib)

NDA/BLA Filed

1st-line advanced hepatocellular carcinoma
Combination Therapy (apatinib)

NDA/BLA Filed
US, Europe, and Asia Pacific (including China)

Relapsed and refractory classical Hodgkin lymphoma
Single Agent

Phase III

Unresectable hepatocellular carcinoma
Combination Therapy (TACE+apatinib)

Phase III

Unresectable locally advanced esophageal cancer
Combination Therapy

Phase III

1st-line advanced cervical cancer
Combination Therapy (famitinib)

Phase III

Maintenance therapy for adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who achieve complete or partial remission with 1st-line platinum-based chemotherapy
Single Agent

Marketed

Metastatic HER2-negative breast cancer with BRCA1/2 mutation
Single Agent/Combination Therapy (apatinib)

Marketed

Recurrent platinum-sensitive gBRCA-mut ovarian carcinoma, fallopian tube carcinoma, or primary peritoneal carcinoma after 2nd-line+ chemotherapy
Single Agent

Marketed

Maintenance therapy for platinum-sensitive recurrent epithelial ovarian carcinoma, fallopian tube carcinoma, or primary peritoneal carcinoma after platinum-containing chemotherapy
Single Agent

Marketed

Metastatic castration-resistant prostate cancer
Combination Therapy (abiraterone)

Phase III
US, Europe, and Asia Pacific (including China)

Relapsed or metastatic HR-positive HER2-negative breast cancer progressed after endocrine therapy
Combination Therapy (fulvestrant)

Marketed

Initial endocrine therapy for locally advanced or metastatic HR-positive HER2-negative breast cancer
Combination Therapy (aromatase inhibitor)

Marketed

Adjuvant therapy for HR-positive, HER2-negative breast cancer
Combination Therapy

Phase III

Lipoprotein disorders
Single Agent

Phase I

Hyperlipidemia
Single Agent

Phase I

Lipoprotein disorders
Single Agent

Phase I

Heart failure
Single Agent

Phase I

Hypertension
Single Agent

Phase I

Diabetes mellitus
Single Agent

Phase II

Prevention of venous thromboembolism after knee arthroplasty
Single Agent

Phase II

Prevention of postoperative venous thromboembolism in patients undergoing ovarian cancer surgery
Single Agent

Phase II

Prevent the risk of stroke or systemic embolism in patients with ventricular fibrillation
Single Agent

Phase I

Obstructive hypertrophic cardiomyopathy
Single Agent

Phase II

Chronic kidney disease
Single Agent

Phase II

Type 2 diabetes mellitus
Single Agent

Phase III

Type 2 diabetes mellitus
Single Agent (FDC)

Phase III

Type 2 diabetes mellitus
Single Agent

Phase III

Overweight or obesity
Single Agent

Phase II

Diabetic kidney disease
Single Agent

Phase II

Overweight or obesity
Single Agent

Phase III

Type 2 diabetes mellitus
Single Agent

Phase III

Obesity with heart failure
Single Agent

Phase II

Obesity with obstructive sleep apnea
Single Agent

Phase II

Obesity with polycystic ovary syndrome
Single Agent

Phase II

Weight management and type 2 diabetes mellitus
Single Agent (tablet)

Phase I

Homozygous familial hypercholesterolemia
Single Agent

Phase III

Hyperlipidemia
Single Agent

Phase II

Type 2 diabetes mellitus
Single Agent (FDC)

NDA/BLA Filed

Type 2 diabetes mellitus
Combination Therapy (metformin+retagliptin)

Marketed

Improve glycemic control in adults with type 2 diabetes mellitus
Single Agent/Combination Therapy (metformin)

Marketed

Chronic kidney disease
Single Agent

Phase II

Type 2 diabetes mellitus
Single Agent/Combination Therapy (metformin)

Marketed

Adults with primary hypercholesterolemia (including heterozygous familial and non-familial hypercholesterolemia) and mixed dyslipidemia who are unable to achieve low-density lipoprotein cholesterol (LDL-C) goals despite moderate or higher doses of statins, or in combination with statins and other lipid-lowering therapies on the basis of dietary control; or as a single agent Adult patients with nonfamilial hypercholesterolemia and mixed dyslipidemia to reduce low-density lipoprotein cholesterol (
Single Agent

Marketed

Inflammatory bowel disease (healthy volunteers)
Single Agent

Phase I
Australia

Inflammatory bowel disease
Single Agent

Phase I

Chronic obstructive pulmonary disease (COPD)
Single Agent

Phase I

Non-cystic fibrosis bronchiectasis
Single Agent

Phase I

Asthma
Single Agent

Phase I

Idiopathic pulmonary fibrosis
Single Agent

Phase I

Asthma
Single Agent

Phase II

Chronic rhinosinusitis with nasal polyp (CRSwNP)
Single Agent

Phase II

Chronic obstructive pulmonary disease
Single Agent

Phase I

Asthma (healthy volunteers)
Single Agent

Phase I
Australia

Atopic dermatitis
Single Agent

Phase III

Prurigo nodularis
Single Agent

Phase III

Chronic spontaneous urticaria
Single Agent

Phase II

Atopic dermatitis in children/adolescents
Single Agent

Phase I

Atopic dermatitis (healthy volunteers)
Single Agent

Phase I
China, Australia

Eosinophilic asthma
Single Agent

Phase III

Eosinophilic granulomatosis with polyangiitis
Single Agent

Phase III

Untreated paroxysmal nocturnal hemoglobinuria
Single Agent

Phase III

Paroxysmal nocturnal hemoglobinuria treated with C5 antibody
Single Agent

Phase III

IgA nephropathy
Single Agent

Phase II

Ankylosing spondylitis
Single Agent

NDA/BLA Filed

Moderate-to-severe active rheumatoid arthritis
Single Agent

NDA/BLA Filed

Moderate-to-severe atopic dermatitis
Single Agent

NDA/BLA Filed
China, Canada

Alopecia
Single Agent

NDA/BLA Filed

Psoriatic arthritis
Single Agent

Phase III

Active radiologically negative mid-axis spondyloarthritis
Single Agent

Phase III

Mild-to-moderate atopic dermatitis
Single Agent (ointment)

Phase III

Ulcerative colitis
Single Agent

Phase III
US, Europe, China

Vitiligo
Single Agent (alkaline gel)

Phase I

Adults with moderate to severe plaque psoriasis who are receiving systemic therapy or phototherapy
Single Agent

Marketed

Active ankylosing spondylitis in adults
Single Agent

NDA/BLA Filed

Moderate-to-severe chronic plaque psoriasis in children and adolescents
Single Agent

Phase III

Psoriatic arthritis
Single Agent

Phase III

Osteoarthritis-related pain
Single Agent

Marketed

Acute ischemic stroke
Single Agent

Phase I

Pain
Single Agent

Phase I

Alzheimer's disease
Single Agent

Phase II

Alzheimer's disease
Single Agent

Phase I
Australia

Severe cerebral edema after massive ischemic stroke
Single Agent

Phase II

MRI of the brain and whole body
Single Agent

Phase II

MRI testing
Single Agent

Phase I
Australia

Post-operative analgesia for abdominal surgeries
Single Agent

Marketed

Moderate to severe pain after orthopedic surgery
Single Agent

NDA/BLA Filed

Sedation and anesthesia in non-endotracheal intubation procedures/procedures, general anesthesia induction and maintenance
Single Agent

Marketed

ICU sedation with mechanical ventilation
Single Agent

Phase III

Severe infections caused by gram-negative bacteria
Single Agent

Phase I

Candidemia or invasive candidiasis
Single Agent

Phase II

Chronic hepatitis B
Single Agent

Phase II

Prevent postoperative nausea and vomiting
Single Agent

Phase II

Complicated urinary tract infection
Single Agent

Phase III

Pulmonary infection
Single Agent

Phase I

Controlled ovarian hyperstimulation
Single Agent

Phase III

Dry eye syndrome associated with meibomian gland dysfunction
Single Agent

NDA/BLA Filed

Severe vulvovaginal candidiasis
Single Agent

Marketed